Rhenman & Partners Asset Management’s Harmony Biosciences HRMY Stock Holding History

Rhenman & Partners Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-81,474	Closed	-$2.67M	–	90
2023 Q3	$2.67M	Sell	81,474 -128,526	-61%	-$4.46M	0.29%	68
2023 Q2	$7.39M	Buy	210,000 +40,000	+24%	+$1.38M	0.78%	43
2023 Q1	$5.56M	Sell	170,000 -70,000	-29%	-$3.19M	0.61%	55
2022 Q4	$13.2M	Buy	240,000 +3,000	+1%	+$165K	1.38%	31
2022 Q3	$12.3M	Sell	237,000 -23,000	-9%	-$1.12M	1.29%	31
2022 Q2	$12.7M	Sell	260,000 -8,244	-3%	-$371K	1.44%	28
2022 Q1	$13.1M	Buy	268,244 +48,244	+22%	+$1.97M	1.29%	32
2021 Q4	$9.53M	Buy	220,000 +15,124	+7%	+$603K	0.63%	56
2021 Q3	$7.85M	Buy	204,876 +104,876	+105%	+$3.38M	0.55%	56
2021 Q2	$2.82M	Buy	+100,000	New	+$3M	0.19%	90

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Rhenman & Partners Asset Management's HRMY Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 81,474 shares — an estimated $2.67M sold.

Rhenman & Partners Asset Management first reported a position in HRMY in Q2 2021 and held it in 10 quarters. The position peaked at $13.2M in Q4 2022. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

Rhenman & Partners Asset Management reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 81,474 Harmony Biosciences shares in Q4 2023, an estimated $2.67M.
Rhenman & Partners Asset Management first reported a position in Harmony Biosciences in Q2 2021 and held it in 10 quarters.
Rhenman & Partners Asset Management's Harmony Biosciences position peaked at $13.2M in Q4 2022.
221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.